Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were
Tweet Content
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off